Moderna announces Singapore expansion

Its new subsidiary will provide a local presence for improved logistics.

Biotechnology company Moderna announced its plans to establish a new subsidiary in Singapore alongside Malaysia, Taiwan, and Hong Kong. With offices in Japan, South Korea, and Australia, Moderna continued its expansion to the Asia-Pacific (APAC) region.

"The year 2021 was a year of impact for Moderna, and I am proud to see continued growth in 2022 as we expand our presence in Asia. After a decade of pioneering the development of our mRNA platform, we were ready to play a critical role in combating the COVID-19 pandemic globally," said CEO Stéphane Bancel.

Moderna is actively recruiting a team to build a strong presence in the market as its mRNA therapeutics pipeline grows to benefit Singapore and the wider region.

The company's plan to establish a local subsidiary reflects the strategic role of Singapore as a leading biomedical sciences hub. Singapore offers many skilled workers, government support for the sector, and a business-friendly regulatory environment.